摘要
目的探讨检测血清人附睾分泌蛋白4(HE4)、糖类抗原153(CA153)在乳腺癌中的临床意义及价值。方法采用化学发光法及ELISA方法测定300例乳腺浸润性导管癌女性患者血清中CA153、HE4的含量,分析CA153、HE4与乳腺癌临床病理因素间的关系及联合检测CA153和HE4与乳腺癌分子亚型的相关性。结果乳腺癌患者CA153阳性率为42.0%,与患者淋巴结转移有明显相关性(P<0.05)。乳腺癌患者HE4阳性率为39.0%,与患者年龄及临床分期有明显相关性(P<0.05)。CA153与HE4联合检测阳性与肿瘤大小、淋巴结状态与临床分期明显相关(P<0.05)。CA153和HE4联合检测在三阴性乳腺癌中阳性率高。结论血清CA153与HE4联合检测可作为乳腺浸润性导管癌辅助诊断指标及乳腺浸润性导管癌生物学行为预测指标,且其与三阴性乳腺癌有一定的相关性。
Objective To discuss the clinical value of the detection of human epididymis protein 4 （HFA） and car- bohydrate antigen 153 （CA153） in breast cancer. Methods The serum level of CA153 was detected by chemilu- minescence method and that of HFA by enzyme-linked immunosorbent assay （ELISA） in 300 breast cancer pa- tients. The correlations between the levels of HFA and CA153 and clinieopathological factors in breast cancer, as well as the correlation between the combined detection of HFA and CA153 and the molecular subtype of breast cancer were analyzed. Results 42. 0% of the breast cancer cases were CA153 positive, which was associated with lymph node metastasis （P 〈 0.05 ）. 39. 0% of the patients were HE4 positive, which was associated with age and TNM stage （P 〈0. 05）. The combined detection of CA153 and HFAt had higher positive result in triple-negative breast cancer. Conclusion The combined detection of serum CA153 and HE4 can be used as an auxiliary index for the diagnosis and predictive index for biological behaviour of invasive ductal breast cancer, as they are related with triple-negative breast cancer.
出处
《中国微生态学杂志》
CAS
CSCD
2015年第5期565-567,共3页
Chinese Journal of Microecology
